2006～2008年南京地区口服降糖药应用分析  

Utilization of Oral Hypoglycemic Drugs in Nanjing During the Period 2006～2008

作　　者：张吉[1] 冯琳[1] 孟玲[1] 戴惠珍[2] 

机构地区：[1]南京医科大学第一附属医院,南京市210029 [2]江苏省医药情报研究所,南京市210004

出　　处：《中国医院用药评价与分析》2009年第9期646-648,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:评价南京地区口服降糖药的应用现状及趋势。方法:系用金额排序法和用药频度排序法,对22家入网医院近3年临床使用的口服降糖药进行统计和分析。结果:3年中南京地区口服降糖药用药总金额逐年上升,其中阿卡波糖3年来均占据金额排名第1位,占总额比例达36%左右。格列齐特占据2006年DDDs排名榜首位,二甲双胍占据2007年、2008年DDDs排名榜首位。结论:口服降糖药近3年来在临床使用基本合理,市场需求潜力大,高效、安全、依从性好的药物受到临床青睐。OBJECTIVE： To evaluate the status quo and tendency of the utilization of oral hypoglycemic drugs in Nanjing.METHORD： The utilization of oral hypoglycemic drugs in 22 hospitals in Nanjing from 2006 to 2008 was analyzed statistically through ranking of the consumption sum and DDDs.RESULTS： The consumption sum of oral hypoglycemic drugs increased year by year,with acarbose topping the consumption sum list of hypoglycemic drugs,accounting for about 36% of the total.In terms of DDDs,Gliclazide took the lead in 2006, while dimethylbiguanide ranked at the first place from 2007to 2008. CONCLUSION： The clinical utilization of oral hypoglycemic drugs over the 3 years was basically rational. The market demand on oral hypoglycemic drugs is potential and those with high efficiency, good safety and tolerability are welcome in the clinic.

关 键 词：口服降糖药 药物利用 南京地区 

分 类 号：R977.15[医药卫生—药品]